Citations

Clear

3942 citation(s) found for "To, Van".

Repeat-associated ataxias in a German patient cohort analysed by targeted parallel long-read sequencing
Erdmann, Hannes , Schaub, Annalisa , Lucas, Morghan C. , Scholz, Veronika , Benet‐Pagès, Anna , Dineiger, Christine, Mayer, Veronika, Buren, Inga Van , Breithausen, Eva, Akbari, Karl, Sauer, Mayra , Krakowsky, Rosanna , Schnabel, Franziska , Dunker, Konstanze, Fabritius, Lena, Gerb, Johannes , Grabova, Denis , Möhwald, Ken , Näher, Marius, Steinmetz, Karoline , Thiessen, Franziska, Jäck, Alexander , Schreyer, Isolde, Mämecke, Larissa, Wilfling, Sibylle, Wunderlich, Gilbert , Hellenbroich, Yorck, Muhle, Kirsten, Claus, Inga, Klopstock, Thomas, Strupp, Michael, Xiong, Chengjie , Huppert, Doreen , Becker‐Bense, Sandra , Filippopulos, Filipp , Kilpert, Fabian , Kaya, Sabine, Schöberl, Florian, Neuhann, Teresa , Holinski‐Feder, Elke , Zwergal, Andreas , Abicht, Angela, Cordts, Isabell , Gerb, Johannes , Brenner, David , Xiong, Chengjie , Kilpert, Fabian , Depienne, Christel , Zwergal, Andreas , Becker, Kerstin , Mayer, Veronika, Akbari, Karl, Schneider, Christine B. , Thiessen, Franziska, Schneider-Gold, Christiane , Zittel, Simone , Petersen, Christina, Huchtemann, Tessa , Höglinger, Günter U. , Leitão, Elsa , Depienne, Christel , Abicht, Angela

Mayo Clinic

Brain | September 1, 2025 | Volume: 149 | Issue: 3 | Pages: 993-1006

10.1093/brain/awaf318 | PMID 40898875 Get It

Abstract Hereditary adult-onset ataxias are a heterogeneous group of phenotypically overlapping conditions, often caused by pathogenic expansions of short tandem repeats. Currently, 18 repeat disorders with a core phenotype of adult-onset ataxia are known. Diagnosis typically relies on sequential PCR-based methods, which are labour-intensive and lack precision. Long-read sequencing (LRS) has the potential to overcome these limitations and is currently implemented and validated in clinical genetics. Using clinical nanopore Cas9-targeted sequencing (Clin-CATS) for parallel in-depth repeat analysis, we evaluated a diagnostic cohort of 513 adult-onset ataxia patients, determining frequencies of all known repeat-associated ataxias except Spinocerebellar ataxia 4 (SCA4), as well as the carrier frequencies for autosomal-recessive disorders, RFC1 spectrum disorder and Friedreich’s ataxia (FRDA). Additionally, phenotypes of patients with established genetic diagnoses were characterized, especially those of patients living with RFC1 spectrum disorder and SCA27B. Repeat-associated ataxias were confirmed in 33.3% of cases, including rare ataxias, such as SCA10, SCA36 and SCA37, alongside as the most prevalent conditions SCA27B and RFC1 spectrum disorder. Potentially pathogenic expansions in FGF14 were identified in an additional 4.7% of patients. Testing of another 347 patients for ZFHX3 expansions linked to SCA4 did not identify any cases. Dual diagnoses were frequent, occurring in 6.4% of patients with repeat-associated ataxia. We confirmed a high RFC1 spectrum disorder carrier frequency (7.2%) and reclassified certain FXN expansions as likely non-pathogenic, resulting in a lower than estimated carrier frequency for FRDA of 0.8%. We also identified novel repeat configurations in several loci and illustrated the high heterogeneity of repeat expansions in RFC1, highlighting it as a potential source of false results when using PCR-based methods. This study underscores the diagnostic advantages of LRS for comprehensive repeat analysis and recommends its adoption as a standard in clinical genetics, replacing Southern blot and PCR-based approaches. Furthermore, based on our findings in a large patient cohort a re-evaluation of existing phenotype-genotype correlations is recommended as well as evaluating additional parameters alongside the repeat length to improve diagnostic precision of repeat analysis.
Atherosclerosis after pre‐eclampsia: systematic review and meta‐analysis
Jansen, Gwyneth , Rooy, A De, Janssen, Emma B N J , Altintas, Sibel , Hof, Arnoud W.J. van ’t , Mihl, Casper , Kietselaer, Bas , Spaanderman, M., Ghossein‐Doha, Chahinda , Jansen, G , Kietselaer, Bas L J H , Spaanderman, Marc E. A.

Mayo Clinic

Ultrasound in Obstetrics & Gynecology | August 31, 2025 | Volume: 67 | Issue: 1 | Pages: 15-26

10.1002/uog.70014 | PMID 40886380 Get It

ABSTRACT Objective Pre‐eclampsia complicates up to 8% of pregnancies and is associated with increased risk of ischemic cardiac and cerebral disease, which may be prevented through management of cardiovascular risk when early disease stages are detected. This meta‐analysis aimed to determine the prevalence of clinical and subclinical atherosclerosis in women after pre‐eclamptic vs non‐pre‐eclamptic pregnancy with advancing maternal age. Methods A systematic search of the literature was conducted in PubMed, Embase and Web of Science for studies reporting on the prevalence of atherosclerosis in women with a previous pre‐eclamptic pregnancy and those with a previous uncomplicated pregnancy. Any systemic atherosclerosis documented using ultrasound or computed tomography was included. Random‐effects meta‐analysis was used to compute the odds ratio (OR) with 95% CI for the association between pre‐eclampsia and the presence of atherosclerosis. Subgroup analysis was conducted according to average maternal age at evaluation. Results A total of 11 articles were included (13 217 participants). The average maternal age at evaluation ranged from 32 to 60 years. Within this age range, the pooled OR for the presence of atherosclerotic plaque after pre‐eclampsia was 1.57 (95% CI, 1.39–1.78). The pooled OR of developing atherosclerotic plaque after a pre‐eclamptic vs non‐pre‐eclamptic pregnancy increased gradually with advancing maternal age. The OR was not significant in the 30–39‐year‐old group (0.64 (95% CI, 0.10–4.15)), but the odds of finding an atherosclerotic plaque were significantly increased after pre‐eclamptic pregnancy in the 40–49‐year‐old group (OR, 1.59 (95% CI, 1.34–1.89)) and 50–60‐year‐old group (OR, 2.00 (95% CI, 1.30–3.08)). At any given age, the percentage plaque prevalence in formerly pre‐eclamptic women was roughly equal to that seen 10 years later in women with a previous non‐pre‐eclamptic pregnancy. Conclusions Women with a previous pre‐eclamptic pregnancy exhibit atherosclerosis more frequently and approximately 10 years earlier compared with women with a previous non‐pre‐eclamptic pregnancy. Targeted primary prevention is required to reduce morbidity and mortality from premature cardiovascular disease in women after pre‐eclampsia. © 2025 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
Prevalence of Hidradenitis Suppurativa
Hagan, Paa Gyasi, Botvid, Sofia , Hove, Lone Storgaard, Christensen, Robin , Group, GHiSA, Knecht-Gurwin, Klaudia , Zobiri, S., Serradj, A. , Noor, Towhida , Guillem, Philippe , Parvizi, Mohammad Mahdi , Vardar, Caner, Maharbi, Waleed H. A. Al, Huijstee, Johanna C. van , Aarts, Pim , Dewi, Shinta Trilaksmi , Indrastuti, Niken , Suryawati, Nyoman , Adji, Aryani , Akhyar, Gardenia , Nopriyati, Nopriyati, Reyes‐Baraona, Francisco, Matas, Carlos, Saeed, Haroon , Moodley, Ameshin , Binamer, Yousef , Kamil, Moonyza Akmal Ahmad , Jocic, Ivana , Mijušković, Željko, Mallawaarachchi, Kanchana , Gangani, Chathurika, Tusheva, Ivana , Boshkovski, Vesna Brishkoska , Hu, Danchen , Medianfar, Cecilia E. , Benhadou, Farida , Naik, Haley B. , Boer, Jurr , Bouazzi, Dorra , Nielsen, Sabrina Mai , Prens, Errol P. , Jemec, Gregor B. E. , Group, GHiSA, Szepietowski, Jacek C. , Anaba, Ehiaghe L. , Chehad, Ahmed Samaouel , Bhuiyan, Mohammed Saiful Islam , Saki, Nasrin , Alpsoy, Erkan , Kanni, Theodora , Giamarellos‐Bourboulis, Evangelos J. , Frew, John W. , Maharbi, Waleed AL, Febriana, Sri Awalia , Pangastuti, Miranti , Nopriyati, Nopriyati , Hazlianda, Cut Putri , Matas, Carlos, Saeed, Haroon, Geng, Songmei , Saunte, Ditte Marie Lindhardt , Chandran, Nisha Suyien , Zee, Hessel H. van der , Zouboulis, Christos C. , Villumsen, Bente , Alavi, Afsáneh , Ibekwe, Perpetua U. , Hamzavi, Iltefat H. , Ingram, John R , Garg, Amit

Mayo Clinic

JAMA Dermatology | August 27, 2025 | Volume: 161 | Issue: 10 | Pages: 1022

10.1001/jamadermatol.2025.2373 | PMID 40864454 Get It

Importance Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with a substantial burden. Standardized global prevalence estimates and data on associated sociodemographic and risk factors are lacking. Objective To estimate the global prevalence of HS and study differences in prevalence by age, sex, geographical location, body mass index (BMI; calculated as weight in kilograms divided by height in meters squared), smoking status, gross domestic product (GDP), and Human Development Index (HDI). Data Sources and Study Selection Included studies were conducted using the standardized Global Hidradenitis Suppurativa Atlas methodology with finalized data collection before May 19, 2023. Studies were required to use a population-based sampling method and conduct clinical confirmation of HS diagnosis following a screening questionnaire. Data Extraction and Synthesis Data were independently extracted from relevant studies by 2 reviewers (D.B. and C.E.M.) using a standardized form. Extracted variables included geographic location, age, sex, BMI (median and BMI >30), smoking status, HS prevalence estimates (with 95% CIs), GDP, and HDI. A proportional meta-analysis using a random-effects model was conducted on the included studies. Main Outcomes and Measures The primary outcome was the point prevalence of HS, confirmed by clinical examination. Secondary outcomes included differences in HS prevalence by sex, age, BMI category, smoking status, and country-level socioeconomic indicators (GDP and HDI). All outcomes were prespecified before data analysis. Results The sample included 22 743 participants, identifying 247 patients with HS, across 25 studies in 23 countries spanning 6 continents. The median proportion of female patients with HS was 55.6%, and the median age was 34.5 years. While the prevalence estimates showed considerable inconsistency ( I 2 > 75%; τ 2 = 0.747), the overall random-effects global prevalence of HS was 0.99% (95% CI, 0.67%-1.46%). Female sex was the only factor observed to be associated with the prevalence estimates (β = 1.02; 95% CI, 1.01-1.03). Conclusions and Relevance In this meta-analysis, an estimated global prevalence of HS between 0.67% and 1.46% surpassed previous global estimates. Substantial global variations in HS prevalence were also observed. Female sex was the only factor associated with prevalence in this sample. Future studies assessing genetic, environmental, and etiological factors are warranted to explain the heterogeneity in prevalence.
Effects of physiological doses of atrial natriuretic peptide on lipolysis, ketogenesis, and glucose metabolism in men
Larsen, Emil List , Andersen, Ulrik Ørsø , Hall, Gerrit van , Lundby, Carsten , Burnett, John C. , Goetze, Jens P. , Plomgaard, Peter , van Hall, Gerrit

Mayo Clinic

American Journal of Physiology-Endocrinology and Metabolism | August 26, 2025 | Volume: 329 | Issue: 4 | Pages: E512-E521

10.1152/ajpendo.00341.2024 | PMID 40857129 Get It

Atrial natriuretic peptide (ANP) is suggested to stimulate lipolysis, which has been demonstrated using supraphysiological doses of ANP. We explored the effects of physiological doses of ANP, as observed during an acute exercise bout, on lipolysis, ketogenesis, and glucose metabolism. Ten healthy men was randomized to infusion of ANP vs. placebo using stable isotope labeled tracers. The present study indicates that lipid metabolism does not seem to be regulated by ANP in men.
Overcoming Barriers to Developing and Implementing Novel Therapies for Hypertension
Lópes, Renato D. , Cargill, Victoria A., Cowie, Martín , Cushman, William C. , Elkind, Mitchell S.V. , Epstein, Shilpi, Garg, Pushkal, Gersh, Bernard J. , Giakoumis, M. , Guo, Weinong, Kirtane, Ajay J. , Lefkowitz, Marty , Lesogor, Anastasia, Ohman, E. Magnus , Pagidipati, Neha J. , Reboussin, David M. , Roessig, Lothar, Roger, Véronique L. , Sánchez, Eduardo , Stockbridge, Norman, Weber, Michael A. , Whelton, Seamus P. , Lopes, Renato D , Cowie, Martin R , Cushman, William C , Elkind, Mitchell S V , Gersh, Bernard J , Giakoumis, Michail , Green, Jennifer B , Kirtane, Ajay J , Lefkowitz, Martin P , Mensah, George A. , O'Donoghue, Michelle L , Ohman, E Magnus , Pagidipati, Neha J , Roger, Veronique L , Sanchez, Eduardo J , Stockbridge, Norman , Touyz, Rhian M , Van Spall, Harriette G C , Weber, Michael A , Whelton, Seamus P , Hernandez, Adrian , Yancy, Clyde W. , Granger, Christopher B , Krychtiuk, Konstantin A , Chen, Roland K. , Ohman, E. Magnus, Touyz, Rhian M. , Spall, Harriette G.C. Van , Hernandez, Adrian F. , Granger, Christopher B.

Mayo Clinic

Hypertension | August 26, 2025 | Volume: 82 | Issue: 10 | Pages: 1599-1611

10.1161/hypertensionaha.125.24992 | PMID 40874957 Get It

Hypertension is the single most important modifiable risk factor for preventable disability and death worldwide and disproportionately affects socially disadvantaged populations. We face a paradox—blood pressure control is low and recent trends suggest it is even declining, despite the availability of inexpensive and effective therapies. A variety of barriers on the system, patient, and healthcare provider side hinder effective drug-based risk factor management. Clinical inertia represents a major barrier on the clinician side, as well as workload and limited education. Common barriers on the patient side include limited English proficiency, low health literacy, and nonadherence with misaligned incentives, limited resources, lack of structured clinical pathways, and reimbursement issues. New innovations in the field of RNA-targeted therapies and device-based interventions could prevent and potentially even cure diseases previously designated as chronic health conditions, such as hypertension. Such novel therapies could potentially overcome several major barriers to effective treatment, including nonadherence. Drug development of novel, long-acting treatments requires consideration of specific clinical trial design aspects, including safety collection, benefit: risk assessment, the development and assessment of novel, qualitative surrogate end points, such as time-in-therapeutic range, the use of representative trial settings as well as the definition of standard of care in placebo-controlled trials, which should be of reasonably high-quality allowing for credible evaluation of effectiveness. Here, we provide an overview on barriers to effective treatment and a framework for trials assessing novel treatments for cardiovascular disease risk factors, including early and broad implementation programs.
Safety and Efficacy Findings From a Phase Ib/ II Study of ASP ‐1929 Photoimmunotherapy With Pembrolizumab in Recurrent and/or Metastatic Head and Neck Squ
Cognetti, David M. , Johnson, Jennifer M. , Kwon, Michael , Su, Shirley Y. , Civantos, Francisco , Valentino, Joseph, Bell, R. Bryan, Abel, Kathryn M. Van , Price, Katharine A. , Dong, Haiying, Thorne, Amy Haseley, Van Abel, Kathryn M , Su, Shirley Y , Curry, Joseph , Olazagasti, Coral , Arnold, Susanne M. , Gibson, Michael K. , Mannion, Kyle , Suzuki, Toshiaki , Gillenwater, Ann Marie

Mayo Clinic

Head & Neck | August 25, 2025 | Volume: 48 | Issue: 1 | Pages: 160-174

10.1002/hed.70014 | PMID 40852760 Get It

ABSTRACT Background ASP‐1929 photoimmunotherapy—cetuximab conjugated to IRDye 700DX and red light (690 nm) for localized drug activation—results in rapid, selective cell killing. Methods This phase Ib/II open‐label study evaluated ASP‐1929 photoimmunotherapy plus pembrolizumab in patients with recurrent/metastatic HNSCC (≥ 1 accessible lesion, PD‐L1 combined positive score ≥ 1, ineligible for standard locoregional therapy). Primary objectives were safety/tolerability and objective response rate (ORR). Secondary objectives included overall survival (OS) and progression‐free survival (PFS). Results Eighteen patients (median age 63 years, 74% male) comprised the photoimmunotherapy‐evaluable population. The confirmed ORR was 27.8% (95% CI 9.7–53.5); four of five responders had complete responses (95% CI, 6.4–47.6). Median OS was 25.6 months (95% CI, 14.6–not evaluable); median PFS was 2.9 months (95% CI, 1.4–14.6). The most common serious adverse reactions were dysphagia and tongue edema (each n = 2; 10.5%). Conclusions ASP‐1929 photoimmunotherapy plus pembrolizumab was generally tolerable, with promising efficacy in patients with recurrent/metastatic HNSCC.
Expert consensus recommendations on appropriate serological testing for the chief complaint of alopecia
Middleton, Hayden T. , Monahan, Erin, James, Garland, Grippe, Kristen, Link, Jenny L. , Chavez, Magdalena, Sominidi‐Damodaran, Sindhuja , Pham, Van Trọng, Franley, Brittney, O’Brien, Jack C. , Whinery, Sarah Jane, James, Garland, Chavez, Magdalena, Pham, Van, Griffith, Cynthia Faires

Mayo Clinic

Journal of Dermatology for Physician Assistants | August 22, 2025 | Volume: 19 | Issue: 3 | Pages: 6-13

10.1097/jdpa.0000000000000067 Get It

Study Design: A panel of 13 clinicians with experience in dermatology and primary care was assembled to review literature regarding the diagnostic workup of scarring and nonscarring alopecias. The literature for review included clinical trials, meta-analyses, systematic reviews, and previously published guidelines from the last 10 years. After review, the panel drafted a list of consensus statements and then voted on these statements using a modified eDelphi method in order to verify the validity and clarity of each statement. Objective: Our objective, as a panel, was to formulate a clear set of guidelines in the workup of various forms of hair loss by a systematic review of clinical data and literature on the matter. Background: Hair loss is a common and frustrating medical concern for patients worldwide and accounts for significant health care utilization and cost. Moreover, hair loss may present as a symptom of an underlying medical condition requiring attention and treatment. Results: After review, the panel reached a total of 22 consensus statements regarding recommendations for diagnostic testing in the setting of hair loss, 17 of those statements focused on nonscarring alopecias, and 5 statements directed toward scarring alopecias. The statements were evaluated by members of the panel and voted on through a modified eDelphi method and discussed in an open forum. Conclusion: The panel’s review revealed that the diagnostic laboratories and/or scalp biopsy should be considered to varying degrees depending on the type of hair loss at presentation. If there is concern for a scarring process, a biopsy should be strongly considered, while serum laboratory work may be of little benefit. In nonscarring alopecias including alopecia areata, telogen effluvium, and androgenetic alopecia, the literature supports ordering certain serologic tests based on the type of hair loss at presentation.
Detection, quantitation, and genotyping of human papillomavirus circulating tumor DNA by droplet digital PCR
Fernholz, Emily C. , Abel, Kathryn M. Van , Moore, Eric J. , Daniel, Jeannie, Hunter, Danielle E., Lewis, James S. , Wendlandt, Erik, Binnicker, Matthew J. , Bartemes, Kathleen R. , Binnicker, Matthew J , Van Abel, Kathryn M , Routman, David M. , Ma, Daniel J.

Mayo Clinic

Journal of Clinical Microbiology | August 19, 2025 | Volume: 63 | Issue: 9 | Pages: No page available

10.1128/jcm.00585-25 | PMID 40827899 Get It

ABSTRACT Human papillomavirus (HPV) is comprised of >200 genotypes and has an ~8 kb, circular, double-stranded DNA genome. Transmission of HPV occurs through skin-to-skin contact and infection of squamous epithelial cells of cutaneous and mucosal surfaces. HPV genotypes are categorized as low- or high-risk (hrHPV) based on oncogenic potential. There are approximately 14 types of hrHPV that can cause several types of cancer, including HPV-associated oropharyngeal squamous cell carcinoma (HPV(+)OPSCC). Detection of HPV(+)OPSCC is traditionally accomplished using p16 immunohistochemistry (IHC) and HPV-specific testing, either DNA or RNA in situ hybridization (ISH) staining or DNA-based PCR of suspected tumor biopsy tissue. More recently, platelet-poor plasma (PPP) samples from patients with HPV(+)OPSCC have proven useful for detection and quantitation of fragments of HPV circulating tumor DNA (ctDNA). ctDNA has been shown to be useful in determining treatment response and monitoring for disease recurrence. In this study, a novel droplet digital PCR assay (ddPCR) was developed and validated for the detection and quantitation of ctDNA from 5 hrHPV genotypes in PPP. Analytical sensitivity ranged from 7.71 to 19.45 fragments of HPV ctDNA per milliliter of PPP across five hrHPV genotypes. In patients with confirmed primary or recurrent HPV(+)OPSCC or HPV(-)OPSCC, testing of corresponding PPP samples ( n = 32) by ddPCR demonstrated 90.63% (29/32) overall agreement with p16/HPV-ISH biopsy results. Compared with reference ddPCR assays performed at outside laboratories, our ddPCR assay yielded 90% (9/10) overall agreement. This assay may provide clinicians with a tool for monitoring HPV ctDNA prior to, during, and after treatment of an HPV-associated cancer. IMPORTANCE At least 14 genotypes of human papillomavirus (HPV) have been identified to have high oncogenic potential. While molecular diagnostic testing for HPV is widely available for liquid cytologic cervical samples, testing is limited for other sample types, including liquid biopsy samples, such as platelet-poor plasma (PPP). With the rising incidence of HPV-associated oropharyngeal squamous cell carcinoma (HPV(+)OPSCC), laboratory testing is an essential part of patient diagnosis, management, and surveillance. Here, we summarize the development and analytical performance validation of a multiplexed, droplet digital PCR (ddPCR) assay for the detection and quantitation of HPV circulating tumor DNA (ctDNA) in PPP. This assay may provide clinicians with a tool to address minimal residual disease for patients with an HPV-associated cancer.